- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MYKOGREEN Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 4,790 | +0,21 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program | Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,270 | 0,00 % | Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft | DJ Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft
Von Elias Schisgall
DOW JONES--Astrazeneca investiert im Rahmen einer erweiterten Partnerschaft 2 Milliarden... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 284,03 | +0,17 % | Praxis Precision Medicine Q2 2026 Earnings Call Transcript | ||
| MBX BIOSCIENCES | 58,54 | 0,00 % | Guggenheim raises MBX Biosciences price target to $150 on obesity drug potential | ||
| QIAGEN | 41,730 | +3,84 % | AKTIEN IM FOKUS: Aktien aus Diagnostik- und Laborbranche gesucht | FRANKFURT (dpa-AFX) - Aktien aus dem Segment Wirkstoffforschung, Diagnostik und Laborausrüstung haben am Dienstag auf den Kauflisten von Anlegern gestanden. Den Dax führten die Papiere von Qiagen und... ► Artikel lesen | |
| BRAVEHEART BIO | 21,350 | 0,00 % | Stifel reiterates Buy on Braveheart Bio stock, $45 target | ||
| AMYLYX PHARMACEUTICALS | 27,780 | 0,00 % | Amylyx Pharma Q2 2026 Earnings Call Transcript | ||
| ERASCA | 14,740 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| NAUTILUS BIOTECHNOLOGY | 1,865 | -0,27 % | Roth/MKM initiates Nautilus Biotechnology stock with buy rating | ||
| EDGEWISE THERAPEUTICS | 40,350 | 0,00 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 45,470 | 0,00 % | This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday | ||
| ARRIVENT BIOPHARMA | 28,460 | 0,00 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2026 Financial Results | Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to... ► Artikel lesen | |
| ABSCI | 11,530 | 0,00 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen | |
| DYNE THERAPEUTICS | 15,450 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,700 | +0,12 % | Beam Therapeutics appoints Eric Foster as Chief Commercial Officer |
MYKOGREEN BIOTECHNOLOGY AG gehört der Branche Biotechnologie an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MYKOGREEN BIOTECHNOLOGY AG finden Sie auf Wallstreet Online.